观察雷贝拉唑、莫沙比利和铝镁加联合治疗反流性食管炎的临床疗效  

View Chaleibeila Azole Clinical Efficacy, Mosapride and Almagate Combination Therapy of Reflux Esophagitis

作　　者：史代萌 

机构地区：[1]河南省南阳市第一人民医院消化内科,河南南阳473000

出　　处：《中国医药指南》2016年第24期126-127,共2页Guide of China Medicine

摘　　要：目的探究反流性食管炎采用雷贝拉唑、莫沙比利联合铝镁加治疗的临床疗效。方法选取反流性食管炎患者60例,随机数字法分为对照组和观察组各组均30例,对照组患者采用雷贝拉唑联合莫沙比利治疗,观察组患者采用雷贝拉唑、莫沙比利与铝镁加联合治疗,观察比较两组患者治疗效果。结果观察组患者治疗总有效率显著高于对照组(P<0.05),患者总反流次数明显少于对照组(P<0.05),数据比较均存在统计学差异。治疗后,两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论反流性食管炎采用雷贝拉唑、莫沙比利联合铝镁加治疗,可有效缓解患者临床症状,减少总反流次数,治疗效果良好,值得临床推广。Objective To explore reflux esophagitis using rabeprazole, mosapride joint Almagate therapy clinical efficacy. Methods 60 cases of reflux esophagitis patients were randomly divided into control group and observation group were 30 cases in each group, the control group were treated with rabeprazole joint mosapride observation group were treated with rabeprazole azole, mosapride and Almagate combination therapy, therapeutic effects were observed between the two groups of patients. Results The patients in the observation group total effective rate was significantly higher （P〈0.05）, the total number of reflux episodes in patients was significantly lower than the control group （P〈0.05）, there were significant differences in the data comparison. After treatment, the two groups of patients the incidence of adverse reactions was no significant difference （P〉0.05）. Conclusion Reflux esophagitis using rabeprazole, mosapride joint Almagate treatment can effectively relieve clinical symptoms, reduce the total number of reflux episodes, the treatment effect is good, worthy of promotion.

关 键 词：反流性食管炎 雷贝拉唑 莫沙比利 铝镁加 临床疗效 

分 类 号：R571[医药卫生—消化系统]